Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q1 2025 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2024 Net Income-$3.99M-$3.99MN/M vs Q1 2024 EPS Diluted-$0.46-$0.46N/M vs Q1 2024 Operating Income-$4,106,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,715,000— ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end